Table 2.
Induction of pyroptosis in cancer by various therapeutic reagents.
Therapeutic Reagents | Cancer Type | Pathway | Refs. |
---|---|---|---|
Docosahexaenoic acid (DHA) | Breast cancer | NF-κB/Caspase-1/GSDMD | [81] |
α-NETA | Ovarian cancer | GSDMD/caspase-4 | [82] |
Polyphyllin VI (PPVI) | NSCLC | ROS/NF-κB/NLRP3/GSDMD | [83] |
Metformin | ESCC | miR-497/PELP1/GSDMD | [84] |
DPP8/9 | AML | CARD8/Caspase-1/GSDMD | [85] |
Cadmium | Breast cancer | [87] | |
BI2536 and Cisplatin | ESCC | [88] | |
Paclitaxel and cisplatin | Lung cancer | Caspase-3/GSDME | [89] |
5-FU | Gastric cancer | [90] | |
BRAFi + MEKi | Melanoma | [91] | |
Doxorubicin | Melanoma | eEF-2K/GSDME | [92] |